Evidence-Based Medicine and Healthcare Quality in the Context of Information Failure: The Case of the UK Fertility Sector View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-08-14

AUTHORS

Minyan Zhu

ABSTRACT

Economic incentives in the context of a particular type of market failure-asymmetric information (which takes place when quality information relating to treatment is not available to patients before purchasing the treatment)-are highly relevant to the understanding of the lack of clinics' incentives to disclose reliable evidence (relating to treatment quality) in the practice of evidence-based medicine. Based on the case study of the UK in vitro fertilisation (IVF) sector, I show that inadequate quality provision (relating to treatment effectiveness and safety) can be associated with a lack of voluntary disclosure of reliable evidence in the practice of evidence-based medicine. In the absence of sufficient economic incentives on clinics to voluntarily acquire and disclose evidence, I discuss the rationale for legislation requiring mandatory evidence disclosure as a possible mechanism to facilitate the acquisition and revelation of evidence. I do so by drawing evidence from the economic literature relating to the impact of such legislation on firms' quality improvement. Practical implications for implementation are discussed (and illustrated with examples in the context of the UK IVF sector) with the purpose to facilitate the role of regulators in setting the standards for evidence disclosure to improve interpretability of such evidence, together with the role of patients in engaging with clinics and verifying such evidence to improve its reliability and, ultimately, quality of care. More... »

PAGES

561-576

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s41669-021-00285-4

DOI

http://dx.doi.org/10.1007/s41669-021-00285-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1140426619

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/34390482


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/14", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1402", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Applied Economics", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Economics, University of Reading, Whiteknights Campus, Reading, RG6 6EL UK", 
          "id": "http://www.grid.ac/institutes/grid.9435.b", 
          "name": [
            "Department of Economics, University of Reading, Whiteknights Campus, Reading, RG6 6EL UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhu", 
        "givenName": "Minyan", 
        "type": "Person"
      }
    ], 
    "datePublished": "2021-08-14", 
    "datePublishedReg": "2021-08-14", 
    "description": "Economic incentives in the context of a particular type of market failure-asymmetric information (which takes place when quality information relating to treatment is not available to patients before purchasing the treatment)-are highly relevant to the understanding of the lack of clinics' incentives to disclose reliable evidence (relating to treatment quality) in the practice of evidence-based medicine. Based on the case study of the UK in vitro fertilisation (IVF) sector, I show that inadequate quality provision (relating to treatment effectiveness and safety) can be associated with a lack of voluntary disclosure of reliable evidence in the practice of evidence-based medicine. In the absence of sufficient economic incentives on clinics to voluntarily acquire and disclose evidence, I discuss the rationale for legislation requiring mandatory evidence disclosure as a possible mechanism to facilitate the acquisition and revelation of evidence. I do so by drawing evidence from the economic literature relating to the impact of such legislation on firms' quality improvement. Practical implications for implementation are discussed (and illustrated with examples in the context of the UK IVF sector) with the purpose to facilitate the role of regulators in setting the standards for evidence disclosure to improve interpretability of such evidence, together with the role of patients in engaging with clinics and verifying such evidence to improve its reliability and, ultimately, quality of care.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s41669-021-00285-4", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1284515", 
        "issn": [
          "2509-4262", 
          "2509-4254"
        ], 
        "name": "PharmacoEconomics - Open", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "5"
      }
    ], 
    "keywords": [
      "evidence-based medicine", 
      "quality of care", 
      "role of patients", 
      "reliable evidence", 
      "healthcare quality", 
      "patients", 
      "clinic", 
      "such evidence", 
      "fertility sector", 
      "quality improvement", 
      "medicine", 
      "possible mechanism", 
      "evidence", 
      "role of regulators", 
      "care", 
      "treatment", 
      "role", 
      "lack", 
      "failure", 
      "practice", 
      "rationale", 
      "absence", 
      "quality", 
      "cases", 
      "study", 
      "regulator", 
      "improvement", 
      "mechanism", 
      "UK", 
      "disclosure", 
      "purpose", 
      "information", 
      "literature", 
      "provision", 
      "particular type", 
      "types", 
      "impact", 
      "standards", 
      "quality information", 
      "implications", 
      "such legislation", 
      "understanding", 
      "acquisition", 
      "context", 
      "reliability", 
      "legislation", 
      "place", 
      "incentives", 
      "quality provision", 
      "implementation", 
      "interpretability", 
      "economic incentives", 
      "case study", 
      "sector", 
      "Practical implications", 
      "revelation", 
      "evidence disclosure", 
      "economic literature", 
      "voluntary disclosure", 
      "sufficient economic incentives", 
      "information failures", 
      "market failure-asymmetric information", 
      "failure-asymmetric information", 
      "clinics' incentives", 
      "fertilisation (IVF) sector", 
      "inadequate quality provision", 
      "mandatory evidence disclosure", 
      "revelation of evidence", 
      "firms' quality improvement", 
      "UK Fertility Sector"
    ], 
    "name": "Evidence-Based Medicine and Healthcare Quality in the Context of Information Failure: The Case of the UK Fertility Sector", 
    "pagination": "561-576", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1140426619"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s41669-021-00285-4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "34390482"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s41669-021-00285-4", 
      "https://app.dimensions.ai/details/publication/pub.1140426619"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T19:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_878.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s41669-021-00285-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s41669-021-00285-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s41669-021-00285-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s41669-021-00285-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s41669-021-00285-4'


 

This table displays all metadata directly associated to this object as RDF triples.

131 TRIPLES      21 PREDICATES      96 URIs      88 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s41669-021-00285-4 schema:about anzsrc-for:14
2 anzsrc-for:1402
3 schema:author Nf40c187d3ee94a6ba336682167e7c5f5
4 schema:datePublished 2021-08-14
5 schema:datePublishedReg 2021-08-14
6 schema:description Economic incentives in the context of a particular type of market failure-asymmetric information (which takes place when quality information relating to treatment is not available to patients before purchasing the treatment)-are highly relevant to the understanding of the lack of clinics' incentives to disclose reliable evidence (relating to treatment quality) in the practice of evidence-based medicine. Based on the case study of the UK in vitro fertilisation (IVF) sector, I show that inadequate quality provision (relating to treatment effectiveness and safety) can be associated with a lack of voluntary disclosure of reliable evidence in the practice of evidence-based medicine. In the absence of sufficient economic incentives on clinics to voluntarily acquire and disclose evidence, I discuss the rationale for legislation requiring mandatory evidence disclosure as a possible mechanism to facilitate the acquisition and revelation of evidence. I do so by drawing evidence from the economic literature relating to the impact of such legislation on firms' quality improvement. Practical implications for implementation are discussed (and illustrated with examples in the context of the UK IVF sector) with the purpose to facilitate the role of regulators in setting the standards for evidence disclosure to improve interpretability of such evidence, together with the role of patients in engaging with clinics and verifying such evidence to improve its reliability and, ultimately, quality of care.
7 schema:genre article
8 schema:inLanguage en
9 schema:isAccessibleForFree true
10 schema:isPartOf N2c2a3dcef1184ca8bf07509cf004c3d5
11 N7df57f17354e47e5b76a0505ed7d07e2
12 sg:journal.1284515
13 schema:keywords Practical implications
14 UK
15 UK Fertility Sector
16 absence
17 acquisition
18 care
19 case study
20 cases
21 clinic
22 clinics' incentives
23 context
24 disclosure
25 economic incentives
26 economic literature
27 evidence
28 evidence disclosure
29 evidence-based medicine
30 failure
31 failure-asymmetric information
32 fertilisation (IVF) sector
33 fertility sector
34 firms' quality improvement
35 healthcare quality
36 impact
37 implementation
38 implications
39 improvement
40 inadequate quality provision
41 incentives
42 information
43 information failures
44 interpretability
45 lack
46 legislation
47 literature
48 mandatory evidence disclosure
49 market failure-asymmetric information
50 mechanism
51 medicine
52 particular type
53 patients
54 place
55 possible mechanism
56 practice
57 provision
58 purpose
59 quality
60 quality improvement
61 quality information
62 quality of care
63 quality provision
64 rationale
65 regulator
66 reliability
67 reliable evidence
68 revelation
69 revelation of evidence
70 role
71 role of patients
72 role of regulators
73 sector
74 standards
75 study
76 such evidence
77 such legislation
78 sufficient economic incentives
79 treatment
80 types
81 understanding
82 voluntary disclosure
83 schema:name Evidence-Based Medicine and Healthcare Quality in the Context of Information Failure: The Case of the UK Fertility Sector
84 schema:pagination 561-576
85 schema:productId N0a869be6cb944bf39f85ccdc4c00d1e5
86 N9924903886634853a35f6d14308478cf
87 Nc39957203ef348e9ad63bf08e35a2df9
88 schema:sameAs https://app.dimensions.ai/details/publication/pub.1140426619
89 https://doi.org/10.1007/s41669-021-00285-4
90 schema:sdDatePublished 2022-01-01T19:01
91 schema:sdLicense https://scigraph.springernature.com/explorer/license/
92 schema:sdPublisher N85dbcddf724e4d298bb64a1e35fc3c2d
93 schema:url https://doi.org/10.1007/s41669-021-00285-4
94 sgo:license sg:explorer/license/
95 sgo:sdDataset articles
96 rdf:type schema:ScholarlyArticle
97 N0a869be6cb944bf39f85ccdc4c00d1e5 schema:name doi
98 schema:value 10.1007/s41669-021-00285-4
99 rdf:type schema:PropertyValue
100 N2c2a3dcef1184ca8bf07509cf004c3d5 schema:issueNumber 4
101 rdf:type schema:PublicationIssue
102 N73cfdb7393bf4dd48702e2082962fc69 schema:affiliation grid-institutes:grid.9435.b
103 schema:familyName Zhu
104 schema:givenName Minyan
105 rdf:type schema:Person
106 N7df57f17354e47e5b76a0505ed7d07e2 schema:volumeNumber 5
107 rdf:type schema:PublicationVolume
108 N85dbcddf724e4d298bb64a1e35fc3c2d schema:name Springer Nature - SN SciGraph project
109 rdf:type schema:Organization
110 N9924903886634853a35f6d14308478cf schema:name pubmed_id
111 schema:value 34390482
112 rdf:type schema:PropertyValue
113 Nc39957203ef348e9ad63bf08e35a2df9 schema:name dimensions_id
114 schema:value pub.1140426619
115 rdf:type schema:PropertyValue
116 Nf40c187d3ee94a6ba336682167e7c5f5 rdf:first N73cfdb7393bf4dd48702e2082962fc69
117 rdf:rest rdf:nil
118 anzsrc-for:14 schema:inDefinedTermSet anzsrc-for:
119 schema:name Economics
120 rdf:type schema:DefinedTerm
121 anzsrc-for:1402 schema:inDefinedTermSet anzsrc-for:
122 schema:name Applied Economics
123 rdf:type schema:DefinedTerm
124 sg:journal.1284515 schema:issn 2509-4254
125 2509-4262
126 schema:name PharmacoEconomics - Open
127 schema:publisher Springer Nature
128 rdf:type schema:Periodical
129 grid-institutes:grid.9435.b schema:alternateName Department of Economics, University of Reading, Whiteknights Campus, Reading, RG6 6EL UK
130 schema:name Department of Economics, University of Reading, Whiteknights Campus, Reading, RG6 6EL UK
131 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...